Condition: Hepatocellular Carcinoma · Advanced Cancer · Sponsor: TaiRx, Inc.
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
This description comes directly from the study's public registry record.
Yen-Ling Chen, PhD · 886-2-2653-5007 · yenlingchen@trx.com.tw
Always discuss trial participation with your own doctor first.
| Kaohsiung Chang Gung Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Keelung Chang Gung Memorial Hospital | Keelung, Taiwan | Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05257590